共 433 条
[1]
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 68 394-424
[2]
Ferlay J(2011)Characterising the castration-resistant prostate cancer population: a systematic review: the epidemiology of CRPC Int J Clin Pract. 65 1180-1192
[3]
Soerjomataram I(2015)Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer Nat Rev Cancer. 15 701-711
[4]
Siegel RL(2008)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol. 26 242-245
[5]
Torre LA(2004)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med. 351 1502-1512
[6]
Jemal A(2013)Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med. 368 138-148
[7]
Kirby M(2014)Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med. 371 424-433
[8]
Hirst C(2017)German multicenter study investigating J Nucl Med. 58 85-90
[9]
Crawford ED(2019)Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients J Nucl Med. 60 955-962
[10]
Watson PA(2016)Clinical outcomes of Clin Nucl Med. 41 522-528